Condition: Thymic Carcinoma · Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.
This description comes directly from the study's public registry record.
Juemin Yu · +8615927548511 · yujm96@163.com
Deping Zhao, MD,PhD · +8613701816883 · zdp1992@163.com
Always discuss trial participation with your own doctor first.
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06019468